Andrx Group ADRX
-
Watson-Andrx Deal to Close
On Tuesday, Watson Pharmaceuticals WPI cleared its final regulatory hurdle to acquire Andrx Group ADRX when the Federal Trade Commission settled on conditions for the transaction. This does not affect our fair value estimate for …
-
Watson, Andrx Await FTC Decision
… Watson Pharmaceuticals WPI expects Federal Trade Commission approval within the next 10 weeks for its acquisition of Andrx Group ADRX . In July, the firms extended their deal closure deadline to mid-November from mid-September to accommodate …
-
Andrx Awaits Merger Approval
Andrx Group ADRX continues to wait for U.S. government approval to cement its merger with Watson Pharmaceuticals WPI. We expect the merger to …
-
Watson to Buy Andrx
Watson Pharmaceuticals WPI agreed Monday to buy Andrx Group ADRX for $25 per share in cash, about 25% above our fair value estimate. We're suspending our fair value estimate for Andrx …
-
Andrx Defeats Toprol XL Patents
On Wednesday, Andrx Group ADRX announced a favorable court ruling that clears the way for the firm to launch its generic version of Toprol XL. While the company …
-
Andrx Faces Its Quality Problems
Andrx ADRX will meet with the Food and Drug Administration later this month to discuss quality-control issues that have blocked the company …
-
Andrx New Drug Approvals on Hold
Tuesday marked a major disappointment for Andrx's ADRX highly volatile generic-drug manufacturing business, as the FDA temporarily halted the approval of new products following a …
-
Andrx Drops the Ball on Concerta
It appears that Andrx ADRX dropped the ball this month on its version of Concerta, its most visible generic candidate. This will probably delay the drug …
-
Andrx under Review
We are placing our fair value estimate for Andrx ADRX under review as we examine the company's third-quarter results, released Wednesday. We don't expect to drop our estimate …
-
Andrx Board Ousts CEO
Andrx Group ADRX announced a change of command Wednesday, replacing Richard Lane with independent board member Thomas Rice as CEO. While we believe …